Global Assisted Reproductive Technology (ART) Market By Offering (Hardware, Software) By Type (In Vitro Fertilization-Embryo Transfer (IVF-ET), Intrafallopian Transfer (Gamete Intrafallopian Transfer (GIFT), Zygote Intrafallopian Transfer (ZIFT), Pronuclear Stage Tubal Transfer (PROST)) Frozen Embryo Transfer (FET), Intracytoplasmic Sperm Injection) By End User (Hospitals and Clinics, Fertility Centers, Research Centers) By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 – 2031
Industry Trends
The use of medical procedures to treat infertility is referred to as assisted reproductive technology (ART). Infertility can affect both men and women. ART treatments include ICSI (intracytoplasmic sperm injection), IVF (in vitro fertilization), cryopreservation of embryos or gametes, fertility drug use, and so on. ART is chiefly used to treat infertility and reproductive endocrinology. According to the most recent WHO figures, around 48 million couples worldwide are infertile. To solve this worldwide health challenge, modern science has developed assisted reproductive technologies. There are several sorts of assisted reproductive technologies, each with its own set of advantages and disadvantages.
Global Assisted Reproductive Technology (ART) Market: Drivers
Changing demographics and cultural views are driving the rise in adoption of assisted reproductive technology (ART) market. ART has substantially accelerated the hunt for appropriate treatment choices for every infertile couple. In order to ease stress and social concerns, the cost and complexity of treatment have been lowered. Multiple pregnancy risks and the use of stimulated cycles have almost all been removed, and innovative ways of treating severe male factor infertility and diagnosing genetic abnormalities in embryos before transfer are now being researched. It is critical that medical treatment, particularly reproductive care, be delivered with utmost care, which in turn is driving the growth of the global assisted reproductive technology (ART) market.
Global Assisted Reproductive Technology (ART) Market: Restraints
Assisted reproductive technology (ART) faces several challenges that can impact its effectiveness, accessibility, and ethical considerations. While ART has evolved significantly and improved success rates over the years, it still does not guarantee a successful pregnancy in every attempt. Success rates vary depending on factors such as age, underlying infertility causes, and the quality of eggs and sperm. The uncertainty of achieving pregnancy with ART procedures can lead to emotional stress and disappointment for individuals and couples. Besides the legal and regulatory frameworks surrounding ART differ across countries and regions. Variations in laws regarding embryo storage, surrogacy, genetic testing, and access to ART services can create challenges and inconsistencies. The absence of comprehensive and standardized regulations can result in legal uncertainties and ethical dilemmas for both patients and providers.
Global Assisted Reproductive Technology (ART) Market Revenue & Forecast, (US$ Million), 2015 – 2031
Global Assisted Reproductive Technology (ART) Market Type Analysis
The frozen embryo transfer (FET) is a procedure in which cryopreserved or frozen embryos from a previous cycle are thawed and placed back into the uterus in order to establish pregnancy. According to the surveys, women between the ages of 35 and 37 who underwent a frozen embryo transfer had a 55% live birth rate and a 66% positive pregnancy test rate. With technological advancements and rising live birth rates, the use of frozen-thawed embryo transfer (FET) has expanded during the last decade. Due to enhanced cryopreservation technology and the option to freeze all embryos, frozen embryo transfer (frozen-ET) is becoming more popular. In addition, many couples undergoing in vitro fertilization (IVF) produce multiple embryos. With the increasing popularity of elective single embryo transfer (eSET) to reduce multiple pregnancies, surplus embryos can be cryopreserved for future use through FET. This has led to a growing number of frozen embryos available for transfer. Thus, higher success rates accompanied with technological advances will support the growth of the global assisted reproductive technology (ART) market during the forecast period 2023-2031.
Global Assisted Reproductive Technology (ART) Market Region-Wise Analysis
North America had the highest share in the global assisted reproductive technology (ART) market in 2022. According to a research, infertility rates among women in the United States have stayed roughly constant over the last two decades. Researchers have discovered that women aged 40 to 44 were 11 times more likely to be infertile than younger women. Overall, the researchers assessed that infertility rates among women in the United States have been around 7% for the previous 20 years. As age is a significant factor in fertility decline, delayed parenthood has led to an increased demand for ART services as people encounter difficulties conceiving naturally. Technological advancements in reproductive medicine have significantly improved the success rates of ART procedures. Innovations in techniques such as IVF, ICSI, and PGT have contributed to higher pregnancy rates, making ART a more appealing option for those struggling with infertility.
Competitive Landscape
The report provides both, qualitative and quantitative research of global assisted reproductive technology (ART) market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global assisted reproductive technology (ART) market are:
- A CooperSurgical Fertility Company
- ART Compass, LLC
- artis
- BIOPSYBELL S.R.L.
- Esco Medical.
- FUJIFILM Irvine Scientific
- gynotec
- IVFtech ApS
- LABOTECT GMBH
- Merck KGaA
- ParaTechs Corporation
- Shivani Scientific
- Vitrolife
- Other Market Participants
Global Assisted Reproductive Technology (ART) Market
By Offering
- Hardware
- Software
By Type
- In vitro fertilization-embryo transfer (IVF-ET)
- Intrafallopian transfer
- Gamete intrafallopian transfer (GIFT)
- Zygote intrafallopian transfer (ZIFT)
- Pronuclear stage tubal transfer (PROST)
- Frozen embryo transfer (FET)
- Intracytoplasmic sperm injection
By End User
- Hospitals and Clinics
- Fertility Centers
- Research Centers
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2021
1.2.2. Base
Year: 2022
1.2.3. Forecast
Years: 2023 – 2031
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Assisted Reproductive Technology (ART)
Market
6. Market Synopsis:
Assisted Reproductive Technology (ART) Market
7. Assisted Reproductive Technology (ART) Market Analysis:
Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Assisted Reproductive Technology (ART) Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Assisted Reproductive Technology (ART) Market
7.6. Porter’s
Five Force Analysis
8. Global Assisted Reproductive Technology (ART) Market Analysis
and Forecasts, 2023 – 2031
8.1. Overview
8.1.1. Global
Assisted Reproductive Technology (ART) Market Revenue (US$ Mn)
8.2. Global
Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and Forecasts,
By Offering
8.2.1. Hardware
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2022
8.2.1.3. Market Forecast, 2023 - 2031
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2022
8.2.1.5.1.2. Market
Forecast, 2023 - 2031
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2022
8.2.1.5.2.2. Market
Forecast, 2023 - 2031
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2022
8.2.1.5.3.2. Market
Forecast, 2023 - 2031
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2022
8.2.1.5.4.2. Market
Forecast, 2023 - 2031
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2022
8.2.1.5.5.2. Market
Forecast, 2023 - 2031
8.2.2. Software
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2022
8.2.2.3. Market Forecast, 2023 - 2031
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2022
8.2.2.5.1.2. Market
Forecast, 2023 - 2031
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2022
8.2.2.5.2.2. Market
Forecast, 2023 - 2031
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2022
8.2.2.5.3.2. Market
Forecast, 2023 - 2031
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2022
8.2.2.5.4.2. Market
Forecast, 2023 - 2031
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2022
8.2.2.5.5.2. Market
Forecast, 2023 - 2031
8.3. Key
Segment for Channeling Investments
8.3.1. By
Offering
9. Global Assisted Reproductive Technology (ART) Market Analysis
and Forecasts, 2023 – 2031
9.1. Overview
9.2. Global
Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and Forecasts,
By Type
9.2.1. In vitro
fertilization-embryo transfer (IVF-ET)
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2022
9.2.1.3. Market Forecast, 2023 - 2031
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2022
9.2.1.5.1.2. Market
Forecast, 2023 - 2031
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2022
9.2.1.5.2.2. Market
Forecast, 2023 - 2031
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2022
9.2.1.5.3.2. Market
Forecast, 2023 - 2031
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2022
9.2.1.5.4.2. Market
Forecast, 2023 - 2031
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2022
9.2.1.5.5.2. Market
Forecast, 2023 - 2031
9.2.2. Intrafallopian
transfer (Definition, Market Estimation and Penetration, 2015 - 2022, Market
Estimation (2015 - 2020), Market Forecast (2023 – 2031), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Gamete intrafallopian
transfer (GIFT), Zygote intrafallopian transfer (ZIFT), Pronuclear stage tubal transfer
(PROST))
9.2.2.1. Gamete intrafallopian transfer (GIFT)
9.2.2.2. Zygote intrafallopian transfer (ZIFT)
9.2.2.3. Pronuclear stage tubal transfer (PROST)
9.2.3. Frozen embryo transfer (FET)
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2022
9.2.3.3. Market Forecast, 2023 - 2031
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2022
9.2.3.5.1.2. Market
Forecast, 2023 - 2031
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2022
9.2.3.5.2.2. Market
Forecast, 2023 - 2031
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2022
9.2.3.5.3.2. Market
Forecast, 2023 - 2031
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2022
9.2.3.5.4.2. Market
Forecast, 2023 - 2031
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2022
9.2.3.5.5.2. Market
Forecast, 2023 - 2031
9.2.4. Intracytoplasmic
sperm injection
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2022
9.2.4.3. Market Forecast, 2023 - 2031
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2022
9.2.4.5.1.2. Market
Forecast, 2023 - 2031
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2022
9.2.4.5.2.2. Market
Forecast, 2023 - 2031
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2022
9.2.4.5.3.2. Market
Forecast, 2023 - 2031
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2022
9.2.4.5.4.2. Market
Forecast, 2023 - 2031
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2022
9.2.4.5.5.2. Market
Forecast, 2023 - 2031
9.3. Key
Segment for Channeling Investments
9.3.1. By Type
10. Global Assisted Reproductive Technology (ART) Market Analysis
and Forecasts, 2023 – 2031
10.1. Overview
10.2. Global
Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and Forecasts,
By End User
10.2.1. Hospitals
and Clinics
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2022
10.2.1.3. Market Forecast, 2023 - 2031
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2022
10.2.1.5.1.2. Market
Forecast, 2023 - 2031
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2022
10.2.1.5.2.2. Market
Forecast, 2023 - 2031
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2022
10.2.1.5.3.2. Market
Forecast, 2023 - 2031
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2022
10.2.1.5.4.2. Market
Forecast, 2023 - 2031
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2022
10.2.1.5.5.2. Market
Forecast, 2023 - 2031
10.2.2. Fertility
Centers
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2022
10.2.2.3. Market Forecast, 2023 - 2031
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2022
10.2.2.5.1.2. Market
Forecast, 2023 - 2031
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2022
10.2.2.5.2.2. Market
Forecast, 2023 - 2031
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2022
10.2.2.5.3.2. Market
Forecast, 2023 - 2031
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2022
10.2.2.5.4.2. Market
Forecast, 2023 - 2031
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2022
10.2.2.5.5.2. Market
Forecast, 2023 - 2031
10.2.3. Research
Centers
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2022
10.2.3.3. Market Forecast, 2023 - 2031
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2022
10.2.3.5.1.2. Market
Forecast, 2023 - 2031
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2022
10.2.3.5.2.2. Market
Forecast, 2023 - 2031
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2022
10.2.3.5.3.2. Market
Forecast, 2023 - 2031
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2022
10.2.3.5.4.2. Market
Forecast, 2023 - 2031
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2022
10.2.3.5.5.2. Market
Forecast, 2023 - 2031
10.3. Key
Segment for Channeling Investments
10.3.1. By End
User
11. North America Assisted Reproductive Technology (ART) Market
Analysis and Forecasts, 2023 – 2031
11.1. Overview
11.1.1. North
America Assisted Reproductive Technology (ART) Market Revenue (US$ Mn)
11.2. North
America Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and
Forecasts, By Offering
11.2.1. Hardware
11.2.2. Software
11.3. North
America Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and
Forecasts, By Type
11.3.1. In
vitro fertilization-embryo transfer (IVF-ET)
11.3.2. Intrafallopian
transfer
11.3.2.1. Gamete intrafallopian transfer (GIFT)
11.3.2.2. Zygote intrafallopian transfer (ZIFT)
11.3.2.3. Pronuclear stage tubal transfer (PROST)
11.3.3. Frozen embryo transfer (FET)
11.3.4. Intracytoplasmic
sperm injection
11.4. North
America Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and
Forecasts, By End User
11.4.1. Hospitals
and Clinics
11.4.2. Fertility
Centers
11.4.3. Research
Centers
11.5. North
America Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and
Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Assisted Reproductive Technology (ART) Market Revenue (US$
Mn) and Forecasts, By Offering
11.5.1.1.1. Hardware
11.5.1.1.2. Software
11.5.1.2. U.S Assisted Reproductive Technology (ART) Market Revenue (US$
Mn) and Forecasts, By Type
11.5.1.2.1. In vitro fertilization-embryo transfer (IVF-ET)
11.5.1.2.2. Intrafallopian transfer
11.5.1.2.2.1. Gamete
intrafallopian transfer (GIFT)
11.5.1.2.2.2. Zygote
intrafallopian transfer (ZIFT)
11.5.1.2.2.3. Pronuclear
stage tubal transfer (PROST)
11.5.1.2.3. Frozen embryo transfer
(FET)
11.5.1.2.4. Intracytoplasmic sperm injection
11.5.1.3. U.S Assisted Reproductive Technology (ART) Market Revenue (US$
Mn) and Forecasts, By End User
11.5.1.3.1. Hospitals and Clinics
11.5.1.3.2. Fertility Centers
11.5.1.3.3. Research Centers
11.5.2. Canada
11.5.2.1. Canada Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Offering
11.5.2.1.1. Hardware
11.5.2.1.2. Software
11.5.2.2. Canada Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
11.5.2.2.1. In vitro fertilization-embryo transfer (IVF-ET)
11.5.2.2.2. Intrafallopian transfer
11.5.2.2.2.1. Gamete
intrafallopian transfer (GIFT)
11.5.2.2.2.2. Zygote
intrafallopian transfer (ZIFT)
11.5.2.2.2.3. Pronuclear
stage tubal transfer (PROST)
11.5.2.2.3. Frozen embryo transfer
(FET)
11.5.2.2.4. Intracytoplasmic sperm injection
11.5.2.3. Canada Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By End User
11.5.2.3.1. Hospitals and Clinics
11.5.2.3.2. Fertility Centers
11.5.2.3.3. Research Centers
11.5.3. Mexico
11.5.3.1. Mexico Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Offering
11.5.3.1.1. Hardware
11.5.3.1.2. Software
11.5.3.2. Mexico Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
11.5.3.2.1. In vitro fertilization-embryo transfer (IVF-ET)
11.5.3.2.2. Intrafallopian transfer
11.5.3.2.2.1. Gamete
intrafallopian transfer (GIFT)
11.5.3.2.2.2. Zygote
intrafallopian transfer (ZIFT)
11.5.3.2.2.3. Pronuclear
stage tubal transfer (PROST)
11.5.3.2.3. Frozen embryo transfer
(FET)
11.5.3.2.4. Intracytoplasmic sperm injection
11.5.3.3. Mexico Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By End User
11.5.3.3.1. Hospitals and Clinics
11.5.3.3.2. Fertility Centers
11.5.3.3.3. Research Centers
11.5.4. Rest of
North America
11.5.4.1. Rest of North America Assisted Reproductive Technology (ART)
Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.4.1.1. Hardware
11.5.4.1.2. Software
11.5.4.2. Rest of North America Assisted Reproductive Technology (ART)
Market Revenue (US$ Mn) and Forecasts, By Type
11.5.4.2.1. In vitro fertilization-embryo transfer (IVF-ET)
11.5.4.2.2. Intrafallopian transfer
11.5.4.2.2.1. Gamete
intrafallopian transfer (GIFT)
11.5.4.2.2.2. Zygote
intrafallopian transfer (ZIFT)
11.5.4.2.2.3. Pronuclear
stage tubal transfer (PROST)
11.5.4.2.3. Frozen embryo transfer
(FET)
11.5.4.2.4. Intracytoplasmic sperm injection
11.5.4.3. Rest of North America Assisted Reproductive Technology (ART)
Market Revenue (US$ Mn) and Forecasts, By End User
11.5.4.3.1. Hospitals and Clinics
11.5.4.3.2. Fertility Centers
11.5.4.3.3. Research Centers
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By
Offering
11.6.3. By Type
11.6.4. By End
User
12. Europe Assisted Reproductive Technology (ART) Market Analysis
and Forecasts, 2023 – 2031
12.1. Overview
12.1.1. Europe
Assisted Reproductive Technology (ART) Market Revenue (US$ Mn)
12.2. Europe
Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and Forecasts,
By Offering
12.2.1. Hardware
12.2.2. Software
12.3. Europe
Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and Forecasts,
By Type
12.3.1. In
vitro fertilization-embryo transfer (IVF-ET)
12.3.2. Intrafallopian
transfer
12.3.2.1. Gamete intrafallopian transfer (GIFT)
12.3.2.2. Zygote intrafallopian transfer (ZIFT)
12.3.2.3. Pronuclear stage tubal transfer (PROST)
12.3.3. Frozen embryo transfer (FET)
12.3.4. Intracytoplasmic
sperm injection
12.4. Europe
Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and Forecasts,
By End User
12.4.1. Hospitals
and Clinics
12.4.2. Fertility
Centers
12.4.3. Research
Centers
12.5. Europe
Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and Forecasts,
By Country
12.5.1. France
12.5.1.1. France Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Offering
12.5.1.1.1. Hardware
12.5.1.1.2. Software
12.5.1.2. France Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.1.2.1. In vitro fertilization-embryo transfer (IVF-ET)
12.5.1.2.2. Intrafallopian transfer
12.5.1.2.2.1. Gamete
intrafallopian transfer (GIFT)
12.5.1.2.2.2. Zygote
intrafallopian transfer (ZIFT)
12.5.1.2.2.3. Pronuclear
stage tubal transfer (PROST)
12.5.1.2.3. Frozen embryo transfer
(FET)
12.5.1.2.4. Intracytoplasmic sperm injection
12.5.1.3. France Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By End User
12.5.1.3.1. Hospitals and Clinics
12.5.1.3.2. Fertility Centers
12.5.1.3.3. Research Centers
12.5.2. The UK
12.5.2.1. The UK Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Offering
12.5.2.1.1. Hardware
12.5.2.1.2. Software
12.5.2.2. The UK Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.2.2.1. In vitro fertilization-embryo transfer (IVF-ET)
12.5.2.2.2. Intrafallopian transfer
12.5.2.2.2.1. Gamete
intrafallopian transfer (GIFT)
12.5.2.2.2.2. Zygote
intrafallopian transfer (ZIFT)
12.5.2.2.2.3. Pronuclear
stage tubal transfer (PROST)
12.5.2.2.3. Frozen embryo transfer
(FET)
12.5.2.2.4. Intracytoplasmic sperm injection
12.5.2.3. The UK Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By End User
12.5.2.3.1. Hospitals and Clinics
12.5.2.3.2. Fertility Centers
12.5.2.3.3. Research Centers
12.5.3. Spain
12.5.3.1. Spain Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Offering
12.5.3.1.1. Hardware
12.5.3.1.2. Software
12.5.3.2. Spain Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.3.2.1. In vitro fertilization-embryo transfer (IVF-ET)
12.5.3.2.2. Intrafallopian transfer
12.5.3.2.2.1. Gamete
intrafallopian transfer (GIFT)
12.5.3.2.2.2. Zygote
intrafallopian transfer (ZIFT)
12.5.3.2.2.3. Pronuclear
stage tubal transfer (PROST)
12.5.3.2.3. Frozen embryo transfer
(FET)
12.5.3.2.4. Intracytoplasmic sperm injection
12.5.3.3. Spain Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By End User
12.5.3.3.1. Hospitals and Clinics
12.5.3.3.2. Fertility Centers
12.5.3.3.3. Research Centers
12.5.4. Germany
12.5.4.1. Germany Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Offering
12.5.4.1.1. Hardware
12.5.4.1.2. Software
12.5.4.2. Germany Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.4.2.1. In vitro fertilization-embryo transfer (IVF-ET)
12.5.4.2.2. Intrafallopian transfer
12.5.4.2.2.1. Gamete
intrafallopian transfer (GIFT)
12.5.4.2.2.2. Zygote
intrafallopian transfer (ZIFT)
12.5.4.2.2.3. Pronuclear
stage tubal transfer (PROST)
12.5.4.2.3. Frozen embryo transfer
(FET)
12.5.4.2.4. Intracytoplasmic sperm injection
12.5.4.3. Germany Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By End User
12.5.4.3.1. Hospitals and Clinics
12.5.4.3.2. Fertility Centers
12.5.4.3.3. Research Centers
12.5.5. Italy
12.5.5.1. Italy Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Offering
12.5.5.1.1. Hardware
12.5.5.1.2. Software
12.5.5.2. Italy Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.5.2.1. In vitro fertilization-embryo transfer (IVF-ET)
12.5.5.2.2. Intrafallopian transfer
12.5.5.2.2.1. Gamete
intrafallopian transfer (GIFT)
12.5.5.2.2.2. Zygote
intrafallopian transfer (ZIFT)
12.5.5.2.2.3. Pronuclear
stage tubal transfer (PROST)
12.5.5.2.3. Frozen embryo transfer
(FET)
12.5.5.2.4. Intracytoplasmic sperm injection
12.5.5.3. Italy Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By End User
12.5.5.3.1. Hospitals and Clinics
12.5.5.3.2. Fertility Centers
12.5.5.3.3. Research Centers
12.5.6. Nordic
Countries
12.5.6.1. Nordic Countries Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Offering
12.5.6.1.1. Hardware
12.5.6.1.2. Software
12.5.6.2. Nordic Countries Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Type
12.5.6.2.1. In vitro fertilization-embryo transfer (IVF-ET)
12.5.6.2.2. Intrafallopian transfer
12.5.6.2.2.1. Gamete
intrafallopian transfer (GIFT)
12.5.6.2.2.2. Zygote
intrafallopian transfer (ZIFT)
12.5.6.2.2.3. Pronuclear
stage tubal transfer (PROST)
12.5.6.2.3. Frozen embryo transfer
(FET)
12.5.6.2.4. Intracytoplasmic sperm injection
12.5.6.3. Nordic Countries Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By End User
12.5.6.3.1. Hospitals and Clinics
12.5.6.3.2. Fertility Centers
12.5.6.3.3. Research Centers
12.5.6.4. Nordic Countries Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux Union Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Offering
12.5.7.1.1. Hardware
12.5.7.1.2. Software
12.5.7.2. Benelux Union Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.7.2.1. In vitro fertilization-embryo transfer (IVF-ET)
12.5.7.2.2. Intrafallopian transfer
12.5.7.2.2.1. Gamete
intrafallopian transfer (GIFT)
12.5.7.2.2.2. Zygote
intrafallopian transfer (ZIFT)
12.5.7.2.2.3. Pronuclear
stage tubal transfer (PROST)
12.5.7.2.3. Frozen embryo transfer
(FET)
12.5.7.2.4. Intracytoplasmic sperm injection
12.5.7.3. Benelux Union Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By End User
12.5.7.3.1. Hospitals and Clinics
12.5.7.3.2. Fertility Centers
12.5.7.3.3. Research Centers
12.5.7.4. Benelux Union Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest of Europe Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Offering
12.5.8.1.1. Hardware
12.5.8.1.2. Software
12.5.8.2. Rest of Europe Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Type
12.5.8.2.1. In vitro fertilization-embryo transfer (IVF-ET)
12.5.8.2.2. Intrafallopian transfer
12.5.8.2.2.1. Gamete
intrafallopian transfer (GIFT)
12.5.8.2.2.2. Zygote
intrafallopian transfer (ZIFT)
12.5.8.2.2.3. Pronuclear
stage tubal transfer (PROST)
12.5.8.2.3. Frozen embryo transfer
(FET)
12.5.8.2.4. Intracytoplasmic sperm injection
12.5.8.3. Rest of Europe Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By End User
12.5.8.3.1. Hospitals and Clinics
12.5.8.3.2. Fertility Centers
12.5.8.3.3. Research Centers
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By
Offering
12.6.3. By Type
12.6.4. By End
User
13. Asia Pacific Assisted Reproductive Technology (ART) Market
Analysis and Forecasts, 2023 – 2031
13.1. Overview
13.1.1. Asia
Pacific Assisted Reproductive Technology (ART) Market Revenue (US$ Mn)
13.2. Asia
Pacific Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and
Forecasts, By Offering
13.2.1. Hardware
13.2.2. Software
13.3. Asia
Pacific Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and
Forecasts, By Type
13.3.1. In
vitro fertilization-embryo transfer (IVF-ET)
13.3.2. Intrafallopian
transfer
13.3.2.1. Gamete intrafallopian transfer (GIFT)
13.3.2.2. Zygote intrafallopian transfer (ZIFT)
13.3.2.3. Pronuclear stage tubal transfer (PROST)
13.3.3. Frozen embryo transfer (FET)
13.3.4. Intracytoplasmic
sperm injection
13.4. Asia
Pacific Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and
Forecasts, By End User
13.4.1. Hospitals
and Clinics
13.4.2. Fertility
Centers
13.4.3. Research
Centers
13.5. Asia
Pacific Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and
Forecasts, By Country
13.5.1. China
13.5.1.1. China Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Offering
13.5.1.1.1. Hardware
13.5.1.1.2. Software
13.5.1.2. China Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
13.5.1.2.1. In vitro fertilization-embryo transfer (IVF-ET)
13.5.1.2.2. Intrafallopian transfer
13.5.1.2.2.1. Gamete
intrafallopian transfer (GIFT)
13.5.1.2.2.2. Zygote
intrafallopian transfer (ZIFT)
13.5.1.2.2.3. Pronuclear
stage tubal transfer (PROST)
13.5.1.2.3. Frozen embryo transfer
(FET)
13.5.1.2.4. Intracytoplasmic sperm injection
13.5.1.3. China Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By End User
13.5.1.3.1. Hospitals and Clinics
13.5.1.3.2. Fertility Centers
13.5.1.3.3. Research Centers
13.5.2. Japan
13.5.2.1. Japan Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Offering
13.5.2.1.1. Hardware
13.5.2.1.2. Software
13.5.2.2. Japan Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
13.5.2.2.1. In vitro fertilization-embryo transfer (IVF-ET)
13.5.2.2.2. Intrafallopian transfer
13.5.2.2.2.1. Gamete
intrafallopian transfer (GIFT)
13.5.2.2.2.2. Zygote
intrafallopian transfer (ZIFT)
13.5.2.2.2.3. Pronuclear
stage tubal transfer (PROST)
13.5.2.2.3. Frozen embryo transfer
(FET)
13.5.2.2.4. Intracytoplasmic sperm injection
13.5.2.3. Japan Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By End User
13.5.2.3.1. Hospitals and Clinics
13.5.2.3.2. Fertility Centers
13.5.2.3.3. Research Centers
13.5.3. India
13.5.3.1. India Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Offering
13.5.3.1.1. Hardware
13.5.3.1.2. Software
13.5.3.2. India Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
13.5.3.2.1. In vitro fertilization-embryo transfer (IVF-ET)
13.5.3.2.2. Intrafallopian transfer
13.5.3.2.2.1. Gamete
intrafallopian transfer (GIFT)
13.5.3.2.2.2. Zygote
intrafallopian transfer (ZIFT)
13.5.3.2.2.3. Pronuclear
stage tubal transfer (PROST)
13.5.3.2.3. Frozen embryo transfer
(FET)
13.5.3.2.4. Intracytoplasmic sperm injection
13.5.3.3. India Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By End User
13.5.3.3.1. Hospitals and Clinics
13.5.3.3.2. Fertility Centers
13.5.3.3.3. Research Centers
13.5.4. New
Zealand
13.5.4.1. New Zealand Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Offering
13.5.4.1.1. Hardware
13.5.4.1.2. Software
13.5.4.2. New Zealand Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Type
13.5.4.2.1. In vitro fertilization-embryo transfer (IVF-ET)
13.5.4.2.2. Intrafallopian transfer
13.5.4.2.2.1. Gamete
intrafallopian transfer (GIFT)
13.5.4.2.2.2. Zygote
intrafallopian transfer (ZIFT)
13.5.4.2.2.3. Pronuclear
stage tubal transfer (PROST)
13.5.4.2.3. Frozen embryo transfer
(FET)
13.5.4.2.4. Intracytoplasmic sperm injection
13.5.4.3. New Zealand Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By End User
13.5.4.3.1. Hospitals and Clinics
13.5.4.3.2. Fertility Centers
13.5.4.3.3. Research Centers
13.5.5. Australia
13.5.5.1. Australia Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Offering
13.5.5.1.1. Hardware
13.5.5.1.2. Software
13.5.5.2. Australia Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Type
13.5.5.2.1. In vitro fertilization-embryo transfer (IVF-ET)
13.5.5.2.2. Intrafallopian transfer
13.5.5.2.2.1. Gamete
intrafallopian transfer (GIFT)
13.5.5.2.2.2. Zygote
intrafallopian transfer (ZIFT)
13.5.5.2.2.3. Pronuclear
stage tubal transfer (PROST)
13.5.5.2.3. Frozen embryo transfer
(FET)
13.5.5.2.4. Intracytoplasmic sperm injection
13.5.5.3. Australia Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By End User
13.5.5.3.1. Hospitals and Clinics
13.5.5.3.2. Fertility Centers
13.5.5.3.3. Research Centers
13.5.6. South
Korea
13.5.6.1. South Korea Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Offering
13.5.6.1.1. Hardware
13.5.6.1.2. Software
13.5.6.2. South Korea Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Type
13.5.6.2.1. In vitro fertilization-embryo transfer (IVF-ET)
13.5.6.2.2. Intrafallopian transfer
13.5.6.2.2.1. Gamete
intrafallopian transfer (GIFT)
13.5.6.2.2.2. Zygote
intrafallopian transfer (ZIFT)
13.5.6.2.2.3. Pronuclear
stage tubal transfer (PROST)
13.5.6.2.3. Frozen embryo transfer
(FET)
13.5.6.2.4. Intracytoplasmic sperm injection
13.5.6.3. South Korea Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By End User
13.5.6.3.1. Hospitals and Clinics
13.5.6.3.2. Fertility Centers
13.5.6.3.3. Research Centers
13.5.7. Southeast
Asia
13.5.7.1. Southeast Asia Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Offering
13.5.7.1.1. Hardware
13.5.7.1.2. Software
13.5.7.2. Southeast Asia Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Type
13.5.7.2.1. In vitro fertilization-embryo transfer (IVF-ET)
13.5.7.2.2. Intrafallopian transfer
13.5.7.2.2.1. Gamete
intrafallopian transfer (GIFT)
13.5.7.2.2.2. Zygote
intrafallopian transfer (ZIFT)
13.5.7.2.2.3. Pronuclear
stage tubal transfer (PROST)
13.5.7.2.3. Frozen embryo transfer
(FET)
13.5.7.2.4. Intracytoplasmic sperm injection
13.5.7.3. Southeast Asia Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By End User
13.5.7.3.1. Hospitals and Clinics
13.5.7.3.2. Fertility Centers
13.5.7.3.3. Research Centers
13.5.7.4. Southeast Asia Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest of Asia Pacific Assisted Reproductive Technology (ART)
Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.8.1.1. Hardware
13.5.8.1.2. Software
13.5.8.2. Rest of Asia Pacific Assisted Reproductive Technology (ART)
Market Revenue (US$ Mn) and Forecasts, By Type
13.5.8.2.1. In vitro fertilization-embryo transfer (IVF-ET)
13.5.8.2.2. Intrafallopian transfer
13.5.8.2.2.1. Gamete
intrafallopian transfer (GIFT)
13.5.8.2.2.2. Zygote
intrafallopian transfer (ZIFT)
13.5.8.2.2.3. Pronuclear
stage tubal transfer (PROST)
13.5.8.2.3. Frozen embryo transfer
(FET)
13.5.8.2.4. Intracytoplasmic sperm injection
13.5.8.3. Rest of Asia Pacific Assisted Reproductive Technology (ART)
Market Revenue (US$ Mn) and Forecasts, By End User
13.5.8.3.1. Hospitals and Clinics
13.5.8.3.2. Fertility Centers
13.5.8.3.3. Research Centers
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By
Offering
13.6.3. By Type
13.6.4. By End
User
14. Middle East and Africa Assisted Reproductive Technology (ART)
Market Analysis and Forecasts, 2023 – 2031
14.1. Overview
14.1.1. Middle
East and Africa Assisted Reproductive Technology (ART) Market Revenue (US$ Mn)
14.2. Middle
East and Africa Assisted Reproductive Technology (ART) Market Revenue (US$ Mn)
and Forecasts, By Offering
14.2.1. Hardware
14.2.2. Software
14.3. Middle
East and Africa Assisted Reproductive Technology (ART) Market Revenue (US$ Mn)
and Forecasts, By Type
14.3.1. In
vitro fertilization-embryo transfer (IVF-ET)
14.3.2. Intrafallopian
transfer
14.3.2.1. Gamete intrafallopian transfer (GIFT)
14.3.2.2. Zygote intrafallopian transfer (ZIFT)
14.3.2.3. Pronuclear stage tubal transfer (PROST)
14.3.3. Frozen embryo transfer (FET)
14.3.4. Intracytoplasmic
sperm injection
14.4. Middle
East and Africa Assisted Reproductive Technology (ART) Market Revenue (US$ Mn)
and Forecasts, By End User
14.4.1. Hospitals
and Clinics
14.4.2. Fertility
Centers
14.4.3. Research
Centers
14.5. Middle
East and Africa Assisted Reproductive Technology (ART) Market Revenue (US$ Mn)
and Forecasts, By Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi Arabia Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Offering
14.5.1.1.1. Hardware
14.5.1.1.2. Software
14.5.1.2. Saudi Arabia Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Type
14.5.1.2.1. In vitro fertilization-embryo transfer (IVF-ET)
14.5.1.2.2. Intrafallopian transfer
14.5.1.2.2.1. Gamete
intrafallopian transfer (GIFT)
14.5.1.2.2.2. Zygote
intrafallopian transfer (ZIFT)
14.5.1.2.2.3. Pronuclear
stage tubal transfer (PROST)
14.5.1.2.3. Frozen embryo transfer
(FET)
14.5.1.2.4. Intracytoplasmic sperm injection
14.5.1.3. Saudi Arabia Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By End User
14.5.1.3.1. Hospitals and Clinics
14.5.1.3.2. Fertility Centers
14.5.1.3.3. Research Centers
14.5.2. UAE
14.5.2.1. UAE Assisted Reproductive Technology (ART) Market Revenue (US$
Mn) and Forecasts, By Offering
14.5.2.1.1. Hardware
14.5.2.1.2. Software
14.5.2.2. UAE Assisted Reproductive Technology (ART) Market Revenue (US$
Mn) and Forecasts, By Type
14.5.2.2.1. In vitro fertilization-embryo transfer (IVF-ET)
14.5.2.2.2. Intrafallopian transfer
14.5.2.2.2.1. Gamete
intrafallopian transfer (GIFT)
14.5.2.2.2.2. Zygote
intrafallopian transfer (ZIFT)
14.5.2.2.2.3. Pronuclear
stage tubal transfer (PROST)
14.5.2.2.3. Frozen embryo transfer
(FET)
14.5.2.2.4. Intracytoplasmic sperm injection
14.5.2.3. UAE Assisted Reproductive Technology (ART) Market Revenue (US$
Mn) and Forecasts, By End User
14.5.2.3.1. Hospitals and Clinics
14.5.2.3.2. Fertility Centers
14.5.2.3.3. Research Centers
14.5.3. Egypt
14.5.3.1. Egypt Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Offering
14.5.3.1.1. Hardware
14.5.3.1.2. Software
14.5.3.2. Egypt Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
14.5.3.2.1. In vitro fertilization-embryo transfer (IVF-ET)
14.5.3.2.2. Intrafallopian transfer
14.5.3.2.2.1. Gamete
intrafallopian transfer (GIFT)
14.5.3.2.2.2. Zygote
intrafallopian transfer (ZIFT)
14.5.3.2.2.3. Pronuclear
stage tubal transfer (PROST)
14.5.3.2.3. Frozen embryo transfer
(FET)
14.5.3.2.4. Intracytoplasmic sperm injection
14.5.3.3. Egypt Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By End User
14.5.3.3.1. Hospitals and Clinics
14.5.3.3.2. Fertility Centers
14.5.3.3.3. Research Centers
14.5.4. Kuwait
14.5.4.1. Kuwait Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Offering
14.5.4.1.1. Hardware
14.5.4.1.2. Software
14.5.4.2. Kuwait Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
14.5.4.2.1. In vitro fertilization-embryo transfer (IVF-ET)
14.5.4.2.2. Intrafallopian transfer
14.5.4.2.2.1. Gamete
intrafallopian transfer (GIFT)
14.5.4.2.2.2. Zygote
intrafallopian transfer (ZIFT)
14.5.4.2.2.3. Pronuclear
stage tubal transfer (PROST)
14.5.4.2.3. Frozen embryo transfer
(FET)
14.5.4.2.4. Intracytoplasmic sperm injection
14.5.4.3. Kuwait Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By End User
14.5.4.3.1. Hospitals and Clinics
14.5.4.3.2. Fertility Centers
14.5.4.3.3. Research Centers
14.5.5. South
Africa
14.5.5.1. South Africa Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Offering
14.5.5.1.1. Hardware
14.5.5.1.2. Software
14.5.5.2. South Africa Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Type
14.5.5.2.1. In vitro fertilization-embryo transfer (IVF-ET)
14.5.5.2.2. Intrafallopian transfer
14.5.5.2.2.1. Gamete
intrafallopian transfer (GIFT)
14.5.5.2.2.2. Zygote
intrafallopian transfer (ZIFT)
14.5.5.2.2.3. Pronuclear
stage tubal transfer (PROST)
14.5.5.2.3. Frozen embryo transfer
(FET)
14.5.5.2.4. Intracytoplasmic sperm injection
14.5.5.3. South Africa Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By End User
14.5.5.3.1. Hospitals and Clinics
14.5.5.3.2. Fertility Centers
14.5.5.3.3. Research Centers
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Assisted Reproductive
Technology (ART) Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.6.1.1. Hardware
14.5.6.1.2. Software
14.5.6.2. Rest of Middle East & Africa Assisted Reproductive
Technology (ART) Market Revenue (US$ Mn) and Forecasts, By Type
14.5.6.2.1. In vitro fertilization-embryo transfer (IVF-ET)
14.5.6.2.2. Intrafallopian transfer
14.5.6.2.2.1. Gamete
intrafallopian transfer (GIFT)
14.5.6.2.2.2. Zygote
intrafallopian transfer (ZIFT)
14.5.6.2.2.3. Pronuclear
stage tubal transfer (PROST)
14.5.6.2.3. Frozen embryo transfer
(FET)
14.5.6.2.4. Intracytoplasmic sperm injection
14.5.6.3. Rest of Middle East & Africa Assisted Reproductive
Technology (ART) Market Revenue (US$ Mn) and Forecasts, By End User
14.5.6.3.1. Hospitals and Clinics
14.5.6.3.2. Fertility Centers
14.5.6.3.3. Research Centers
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By
Offering
14.6.3. By Type
14.6.4. By End
User
15. Latin America Assisted Reproductive Technology (ART) Market
Analysis and Forecasts, 2023 – 2031
15.1. Overview
15.1.1. Latin
America Assisted Reproductive Technology (ART) Market Revenue (US$ Mn)
15.2. Latin
America Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and
Forecasts, By Offering
15.2.1. Hardware
15.2.2. Software
15.3. Latin
America Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and
Forecasts, By Type
15.3.1. In
vitro fertilization-embryo transfer (IVF-ET)
15.3.2. Intrafallopian
transfer
15.3.2.1. Gamete intrafallopian transfer (GIFT)
15.3.2.2. Zygote intrafallopian transfer (ZIFT)
15.3.2.3. Pronuclear stage tubal transfer (PROST)
15.3.3. Frozen embryo transfer (FET)
15.3.4. Intracytoplasmic
sperm injection
15.4. Latin
America Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and
Forecasts, By End User
15.4.1. Hospitals
and Clinics
15.4.2. Fertility
Centers
15.4.3. Research
Centers
15.5. Latin
America Assisted Reproductive Technology (ART) Market Revenue (US$ Mn) and
Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Offering
15.5.1.1.1. Hardware
15.5.1.1.2. Software
15.5.1.2. Brazil Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By Type
15.5.1.2.1. In vitro fertilization-embryo transfer (IVF-ET)
15.5.1.2.2. Intrafallopian transfer
15.5.1.2.2.1. Gamete
intrafallopian transfer (GIFT)
15.5.1.2.2.2. Zygote
intrafallopian transfer (ZIFT)
15.5.1.2.2.3. Pronuclear
stage tubal transfer (PROST)
15.5.1.2.3. Frozen embryo transfer
(FET)
15.5.1.2.4. Intracytoplasmic sperm injection
15.5.1.3. Brazil Assisted Reproductive Technology (ART) Market Revenue
(US$ Mn) and Forecasts, By End User
15.5.1.3.1. Hospitals and Clinics
15.5.1.3.2. Fertility Centers
15.5.1.3.3. Research Centers
15.5.2. Argentina
15.5.2.1. Argentina Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Offering
15.5.2.1.1. Hardware
15.5.2.1.2. Software
15.5.2.2. Argentina Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By Type
15.5.2.2.1. In vitro fertilization-embryo transfer (IVF-ET)
15.5.2.2.2. Intrafallopian transfer
15.5.2.2.2.1. Gamete
intrafallopian transfer (GIFT)
15.5.2.2.2.2. Zygote
intrafallopian transfer (ZIFT)
15.5.2.2.2.3. Pronuclear
stage tubal transfer (PROST)
15.5.2.2.3. Frozen embryo transfer
(FET)
15.5.2.2.4. Intracytoplasmic sperm injection
15.5.2.3. Argentina Assisted Reproductive Technology (ART) Market
Revenue (US$ Mn) and Forecasts, By End User
15.5.2.3.1. Hospitals and Clinics
15.5.2.3.2. Fertility Centers
15.5.2.3.3. Research Centers
15.5.3. Rest of
Latin America
15.5.3.1. Rest of Latin America Assisted Reproductive Technology (ART)
Market Revenue (US$ Mn) and Forecasts, By Offering
15.5.3.1.1. Hardware
15.5.3.1.2. Software
15.5.3.2. Rest of Latin America Assisted Reproductive Technology (ART)
Market Revenue (US$ Mn) and Forecasts, By Type
15.5.3.2.1. In vitro fertilization-embryo transfer (IVF-ET)
15.5.3.2.2. Intrafallopian transfer
15.5.3.2.2.1. Gamete
intrafallopian transfer (GIFT)
15.5.3.2.2.2. Zygote
intrafallopian transfer (ZIFT)
15.5.3.2.2.3. Pronuclear
stage tubal transfer (PROST)
15.5.3.2.3. Frozen embryo transfer
(FET)
15.5.3.2.4. Intracytoplasmic sperm injection
15.5.3.3. Rest of Latin America Assisted Reproductive Technology (ART)
Market Revenue (US$ Mn) and Forecasts, By End User
15.5.3.3.1. Hospitals and Clinics
15.5.3.3.2. Fertility Centers
15.5.3.3.3. Research Centers
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By
Offering
15.6.3. By Type
15.6.4. By End
User
16. Competitive Benchmarking
16.1. Market
Share Analysis, 2022
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player Profiles
17.1. A
CooperSurgical Fertility Company
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. ART
Compass, LLC
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. artis
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. BIOPSYBELL
S.R.L.
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Esco
Medical.
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. FUJIFILM
Irvine Scientific
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. gynotec
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. IVFtech
ApS
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. LABOTECT
GMBH
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Merck
KGaA
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. ParaTechs
Corporation
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. Shivani
Scientific
17.12.1. Company
Details
17.12.2. Company
Overview
17.12.3. Product
Offerings
17.12.4. Key
Developments
17.12.5. Financial
Analysis
17.12.6. SWOT
Analysis
17.12.7. Business
Strategies
17.13. Vitrolife
17.13.1. Company
Details
17.13.2. Company
Overview
17.13.3. Product
Offerings
17.13.4. Key
Developments
17.13.5. Financial
Analysis
17.13.6. SWOT
Analysis
17.13.7. Business Strategies
17.14. Other
market participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.